Abstract
Pulmonary metastasectomy is a widely accepted treatment for many patients with pulmonary metastases from various solid tumors. Nevertheless, 5-year survival is disappointing, with rates of 25-40%, and many patients develop recurrences. Isolated lung perfusion (ILuP) is a promising new technique to deliver high-dose chemotherapy to the lungs, while minimising systemic toxicities. This procedure is technically safe and feasible; however, clinical value and efficacy remain unclear. The aim of this paper is to give a review of literature on ILuP in humans, and to describe the development of the perfusion procedure in our institute.
MeSH terms
-
Animals
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / therapeutic use
-
Blood Transfusion, Autologous
-
Carcinoma / drug therapy
-
Carcinoma / secondary
-
Carcinoma / therapy
-
Chemotherapy, Cancer, Regional Perfusion / instrumentation
-
Chemotherapy, Cancer, Regional Perfusion / methods*
-
Clinical Trials, Phase I as Topic
-
Combined Modality Therapy
-
Drug Screening Assays, Antitumor
-
Embolism, Air / prevention & control
-
Equipment Design
-
Extracorporeal Membrane Oxygenation / instrumentation
-
Feasibility Studies
-
Humans
-
Hydroxyethyl Starch Derivatives
-
Hyperthermia, Induced
-
Intraoperative Complications / prevention & control
-
Isotonic Solutions
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / secondary*
-
Lung Neoplasms / therapy
-
Melphalan / administration & dosage
-
Melphalan / therapeutic use
-
Pilot Projects
-
Rheology
-
Ringer's Lactate
-
Sarcoma / drug therapy
-
Sarcoma / secondary
-
Sarcoma / therapy
-
Solutions
-
Temperature
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
HES 130-0.4
-
Hydroxyethyl Starch Derivatives
-
Isotonic Solutions
-
Ringer's Lactate
-
Solutions
-
Melphalan